CAMBRIDGE, Mass., Dec 5, 2024 --- Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company , announced that it has successfully closed the highly anticipated Pharma.AI week webinar series, with over 500 attendees from 63 countries all over the world, witnessing the release of reinforced generative AI platforms, and the highlights are listed below:
Science42: DORA , the AI Agent-based Intelligent Writing Assistant
PandaOmics , the Target Discovery and Prioritization Engine
Chemistry42 , the Generative AI-powered Molecule Generation Platform
Generative Biologics , the AI Tool for De Novo Protein Engineering
"The recent updates to Pharma.AI represent a major leap forward, as we keep integrating cutting-edge AI models and dataset expansion," says Petrina Kamya, PhD, Vice President and Global Head of AI Platforms and President of Insilico Medicine Canada . "For example, Generative Biologics has incorporated user data-based model retraining and improved its generative and reward models, achieving an 8% increase in accuracy and a 25% boost in speed. With the power of generative AI, we hope to further streamline the innovation process, in the pharmaceutical industry and beyond."
In 2016, Insilico first described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal, which laid the foundation for the commercially available Pharma.AI platform. Since then, Insilico keeps integrating technical breakthroughs into Pharma.AI platform, which is currently a generative AI-powered solution spanning across biology, chemistry and clinical development. Powered by Pharma.AI, Insilico has nominated 20 preclinical candidates in its comprehensive portfolio of over 30 assets since 2021 and has received IND approval for 10 molecules.
"It is amazing to see how Pharma.AI grew into the comprehensive generative AI platform today, through the endless innovation our team has been striving for," says Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine . "Our aspirations are to continue pushing the boundaries of what is possible in drug discovery and scientific breakthrough, making the process faster, more cost-effective, and highly precise. "
In early 2024, Insilico published a Nature Biotechnology paper presenting the entire R&D journey from AI algorithms to Phase II clinical trials of ISM001-055, the company’s lead drug pipeline with AI-discovered target and AI-designed structure. Following that, Insilico has recently announced positive preliminary results from a Phase IIa trial (NCT05938920) , where ISM001-055 showed favorable safety and tolerability across all dose levels, as well as dose-dependent response in forced vital capacity (FVC) , after only 12 weeks of dosage.
About Insilico Medicine
Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.